个性化文献订阅>文章检索

文章名     作者     期刊名     摘要     卷     期         如果没有找到您所需要的文献，请点击 ——此处申请     共27条记录   Effects of Anti-VEGF Treatment Duration on Tumor Growth, Tumor Regrowth, and Treatment Efficacy [作者：Bagri, A; Berry, L; Gunter, B; Singh, M; Kasman, I; Damico, LA; Hong, XA; Schmidt, M; Fuh, G; Hollister, B; Rosen, O; Plowman, GD,期刊：Clinical Cancer Research, 页码：3887-3900 , 文章类型： Article，,卷期：2010年16-15] Purpose: Inhibition of the vascular endothelial growth factor (VEGF) axis is the basis of all currently approved antiangiogenic therapies. In preclinical models, anti-VEGF blocking antibodies have shown broad efficacy th... Cytotoxicity of Activated Natural Killer Cells against Pediatric Solid Tumors [作者：Cho, D; Shook, DR; Shimasaki, N; Chang, YH; Fujisaki, H; Campana, D,期刊：Clinical Cancer Research, 页码：3901-3909 , 文章类型： Article，,卷期：2010年16-15] Purpose: To develop new therapies for children with solid tumors, we tested the cytotoxicity of natural killer (NK) cells expanded by coculture with K562-mb15-41BBL cells. We sought to identify the most sensitive tumor s... Targeted Gene Silencing Using RGD-Labeled Chitosan Nanoparticles [作者：Han, HD; Mangala, LS; Lee, JW; Shahzad, MMK; Kim, HS; Shen, DY; Nam, EJ; Mora, EM; Stone, RL; Lu, CH; Lee, SJ; Roh, JW; Nick, AM; Lopez-Berestein, G; Sood, AK,期刊：Clinical Cancer Research, 页码：3910-3922 , 文章类型： Article，,卷期：2010年16-15] Purpose: This study aimed to develop an Arg-Gly-Asp (RGD) peptide-labeled chitosan nanoparticle (RGD-CH-NP) as a novel tumor targeted delivery system for short interfering RNA (siRNA).Experimental Design: RGD peptide con... The Combination of a Histone Deacetylase Inhibitor with the Bcl-2 Homology Domain-3 Mimetic GX15-070 Has Synergistic Antileukemia Activity by Activating Both Apoptosis and Autophagy [作者：Wei, Y; Kadia, T; Tong, WG; Zhang, M; Jia, Y; Yang, H; Hu, YM; Tambaro, FP; Viallet, J; O'Brien, S; Garcia-Manero, G,期刊：Clinical Cancer Research, 页码：3923-3932 , 文章类型： Article，,卷期：2010年16-15] Purpose: Single-agent histone deacetylase inhibitors (HDACi) have limited clinical activity in human leukemia. Although the way HDACi exert their antileukemia effect is not fully understood, it is accepted that induction... Inhibition of Src Impairs the Growth of Met-Addicted Gastric Tumors [作者：Bertotti, A; Bracco, C; Girolami, F; Torti, D; Gastaldi, S; Galimi, F; Medico, E; Elvin, P; Comoglio, PM; Trusolino, L,期刊：Clinical Cancer Research, 页码：3933-3943 , 文章类型： Article，,卷期：2010年16-15] Purpose: We examined whether inhibition of Src tyrosine kinase, a downstream effector of the MET oncogene, can hinder the malignant properties of gastric tumors dependent on Met for growth and survival.Experimental Desig... Metabolic Approach to the Enhancement of Antitumor Effect of Chemotherapy: a Key Role of Acetyl-L-Carnitine [作者：Pisano, C; Vesci, L; Milazzo, FM; Guglielmi, MB; Fodera, R; Barbarino, M; D'Incalci, M; Zucchetti, M; Petrangolini, G; Tortoreto, M; Perego, P; Zuco, V; Orlandi, A; Passeri, D; Carminati, P; Cavazza, C; Zunino, F,期刊：Clinical Cancer Research, 页码：3944-3953 , 文章类型： Article，,卷期：2010年16-15] Purpose: Acetyl-L-carnitine (ALC) plays a relevant role in energy metabolism and stress response because of its function in the complex metabolic system regulating the acetyl-CoA levels that provide a source of acetyl gr... Epithelial Membrane Protein-2 Is a Novel Therapeutic Target in Ovarian Cancer [作者：Fu, MY; Maresh, EL; Soslow, RA; Alavi, M; Mah, V; Zhou, Q; Iasonos, A; Goodglick, L; Gordon, LK; Braun, J; Wadehra, M,期刊：Clinical Cancer Research, 页码：3954-3963 , 文章类型： Article，,卷期：2010年16-15] Purpose: The tetraspan protein epithelial membrane protein-2 (EMP2) has been shown to regulate the surface display and signaling from select integrin pairs, and it was recently identified as a prognostic biomarker in hum... A Novel FRET-Based Biosensor for the Measurement of BCR-ABL Activity and Its Response to Drugs in Living Cells [作者：Mizutani, T; Kondo, T; Darmanin, S; Tsuda, M; Tanaka, S; Tobiume, M; Asaka, M; Ohba, Y,期刊：Clinical Cancer Research, 页码：3964-3975 , 文章类型： Article，,卷期：2010年16-15] Purpose: To develop a novel diagnostic method for the assessment of drug efficacy in chronic myeloid leukemia (CML) patients individually, we generated a biosensor that enables the evaluation of BCR-ABL kinase activity i... Genetically Abnormal Circulating Cells in Lung Cancer Patients: An Antigen-Independent Fluorescence In situ Hybridization-Based Case-Control Study [作者：Katz, RL; He, WG; Khanna, A; Fernandez, RL; Zaidi, TM; Krebs, M; Caraway, NP; Zhang, HZ; Jiang, F; Spitz, MR; Blowers, DP; Jimenez, CA; Mehran, RJ; Swisher, SG; Roth, JA; Morris, JS; Etzel, CJ; El-Zein, R,期刊：Clinical Cancer Research, 页码：3976-3987 , 文章类型： Article，,卷期：2010年16-15] Purpose: We performed a study to determine if a fluorescence in situ hybridization (FISH)-based assay using isolated peripheral blood mononuclear cells (PBMCs) with DNA probes targeting specific sites on chromosomes know... BCIRG 001 Molecular Analysis: Prognostic Factors in Node-Positive Breast Cancer Patients Receiving Adjuvant Chemotherapy [作者：Dumontet, C; Krajewska, M; Treilleux, I; Mackey, JR; Martin, M; Rupin, M; Lafanechere, L; Reed, JC,期刊：Clinical Cancer Research, 页码：3988-3997 , 文章类型： Article，,卷期：2010年16-15] Purpose: There are currently no validated factors predictive of response to taxanes in patients with breast cancer. We analyzed specimens from patients included in the Breast Cancer International Research Group (BCIRG) 0... Phase II Trial of Short-Course R-Chop Followed by Y-90-Ibritumomab Tiuxetan in Previously Untreated High-Risk Elderly Diffuse Large B-Cell Lymphoma Patients [作者：Zinzani, PL; Rossi, G; Franceschetti, S; Botto, B; Di Rocco, A; Cabras, MG; Petti, MC; Stefoni, V; Broccoli, A; Fanti, S; Pellegrini, C; Montini, GC; Gandolfi, L; Derenzini, E; Argnani, L; Fina, M; Tucci, A; Bottelli, C; Pileri, S; Baccarani, M,期刊：Clinical Cancer Research, 页码：3998-4004 , 文章类型： Article，,卷期：2010年16-15] Purpose: This study aimed to evaluate the efficacy and safety of the treatment with Y-90-ibritumomab tiuxetan following a short-course of rituximab with cyclophosphamide-adriamycin-vincristine-prednisone (R-CHOP) in high... Phase I/II Study of Oncolytic HSVGM-CSF in Combination with Radiotherapy and Cisplatin in Untreated Stage III/IV Squamous Cell Cancer of the Head and Neck [作者：Harrington, KJ; Hingorani, M; Tanay, MA; Hickey, J; Bhide, SA; Clarke, PM; Renouf, LC; Thway, K; Sibtain, A; McNeish, IA; Newbold, KL; Goldsweig, H; Coffin, R; Nutting, CM,期刊：Clinical Cancer Research, 页码：4005-4015 , 文章类型： Article，,卷期：2010年16-15] Purpose: This study sought to define the recommended dose of JS1/34.5-/47-/GM-CSF, an oncolytic herpes simplex type-1 virus (HSV-1) encoding human granulocyte-macrophage colony-stimulating factor (GM-CSF), for future stu... A Single-Dose, Crossover, Placebo- and Moxifloxacin-Controlled Study to Assess the Effects of Neratinib (HKI-272) on Cardiac Repolarization in Healthy Adult Subjects [作者：Hug, B; Abbas, R; Leister, C; Burns, J; Sonnichsen, D,期刊：Clinical Cancer Research, 页码：4016-4023 , 文章类型： Article，,卷期：2010年16-15] Purpose: Neratinib is an orally administered, small-molecule, irreversible pan-ErbB inhibitor in development for the treatment of ErbB2-positive breast cancer. This study assessed the effects of therapeutic and suprather... Inhaled Granulocyte-Macrophage Colony Stimulating Factor for First Pulmonary Recurrence of Osteosarcoma: Effects on Disease-Free Survival and Immunomodulation. A Report From the Children's Oncology Group [作者：Arndt, CAS; Koshkina, NV; Inwards, CY; Hawkins, DS; Krailo, MD; Villaluna, D; Anderson, PM; Goorin, AM; Blakely, ML; Bernstein, M; Bell, SA; Ray, K; Grendahl, DC; Marina, N; Kleinerman, ES,期刊：Clinical Cancer Research, 页码：4024-4030 , 文章类型： Article，,卷期：2010年16-15] Purpose: Osteosarcoma most commonly recurs in the lung. Based on preliminary data on the antitumor effects of granulocyte-macrophage colony stimulating factor (GM-CSF) in animal models, and promising phase I trials, we e... Patients with Advanced Head and Neck Cancers Have Similar Progression-Free Survival on Phase I Trials and Their Last Food and Drug Administration-Approved Treatment [作者：Garrido-Laguna, I; Janku, F; Falchook, GS; Fu, SQ; Hong, DS; Naing, A; Aaron, J; Wang, XM; Kies, M; Kurzrock, R,期刊：Clinical Cancer Research, 页码：4031-4037 , 文章类型： Article，,卷期：2010年16-15] Purpose: To compare clinical outcomes of metastatic head and neck cancer patients treated in phase I clinical trials with clinical outcomes of those patients who had their last Food and Drug Administration (FDA)-approved... Phase I Dose Finding Studies of Obatoclax (GX15-070), a Small Molecule Pan-BCL-2 Family Antagonist, in Patients with Advanced Solid Tumors or Lymphoma [作者：Hwang, JJ; Kuruvilla, J; Mendelson, D; Pishvaian, MJ; Deeken, JF; Siu, LL; Berger, MS; Viallet, J; Marshall, JL,期刊：Clinical Cancer Research, 页码：4038-4045 , 文章类型： Article，,卷期：2010年16-15] Purpose: Two phase I, single-agent studies were conducted to determine the dose and regimen of obatoclax, an antagonist of all BCL-2 antiapoptotic proteins, for evaluation in phase II trials. The two studies, GX001 and G...